Abstract

To understand the efficacy and safety of preferred hepatectomy combined with postoperative systemic drug therapy for breast cancer liver metastases is the objective of the study. We retrospectively analyzed 3 patients with liver metastases included in the initial metastatic sites after breast cancer surgery that preferred hepatectomy and postoperative systemic drug therapy in our department between October 2016 and November 2019, combined with literature review to share our experience. All patients were estrogen receptor and/or human epidermal growth factor receptor-2 positive with good performance status and no obvious drug resistance but still had some unfavorable factors. Patient 1 was 73 y old; patient 2 developed 8 liver metastases after only 7 mo after breast surgery and patient 3 had the largest (6.3 cm) liver metastatic lesion and simultaneous extra-hepatic lymph nodes metastases. They all underwent radical (R0) resection of hepatectomy without complications, combined with systemic drug therapy including timely postoperative chemotherapy, sequential targeted therapy and endocrine therapy. During 28-64 mo of follow-up, they all have eventually achieved clinically complete remission of tumor in the whole body with good quality of life. The longest progression-free survival has been above 64 mo. Preferred hepatectomy combined with postoperative systemic drug therapy was safe and may benefit for estrogen receptor and/or human epidermal growth factor receptor-2 positive breast cancer patients with liver included in the initial metastatic sites who had good performance status, no drug resistance, potential R0 resection, limited and controllable extrahepatic metastasis.